BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

DEFENDER PHARMACEUTICALS, INC. — Lobbying — Receipts Report

LD-2 disclosure · 4th Quarter - Report

DEFENDER PHARMACEUTICALS, INC.

via AMERICAN DEFENSE INTERNATIONAL

4th Quarter (Oct 1 - Dec 31) · 2023Posted Jan 16, 2024Filing document ↗LDA record ↗

Coverage · No income or expenses were reported on this filing.

Client

Name: DEFENDER PHARMACEUTICALS, INC.
Description: Pharmaceuticals
Location: Florida · United States of America

Registrant

Firm: AMERICAN DEFENSE INTERNATIONAL
Description: Lobbying and consulting firm.
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Defense
H.R. 2670: National Defense Authorization Act (NDAA), provisions related to scopolamine research.
LobbyistsVAN HIPP jr
TargetedHOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.